Synergy to initiate Phase 3 plecanatide CIC trial in Q4

Synergy Pharmaceuticals (SGYP) completes an end-of-Phase 2 meeting with the FDA regarding plecanatide for the treatment of chronic idiopathic constipation.

The company and the regulator reach an agreement on the requirements and specifications for a Phase 3 pivotal program which will begin in Q4. (PR)

Shares +3.26% premarket.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs